Tassis, Panagiotis
Pel, Suzanne
Floros, Dimitrios
Haar, Kim ter
Cao, Qi
Tsakmakidis, Ioannis
Papatsiros, Vassileios
Ntarampa, Niki
Arsenakis, Ioannis
Tzika, Eleni D.
Funding for this research was provided by:
MSD Animal Health (72834, 72834, 72834, 72834, 72834, 72834, 72834)
Article History
Received: 6 November 2024
Accepted: 5 March 2025
First Online: 7 April 2025
Declarations
:
: The trial farm owner has provided a written consent for participation to the study. This study protocol was reviewed and approved according to the relevant regulatory standards from the Research Ethics Committee of the Aristotle University of Thessaloniki (AUTH) with approval number 112724 /2021 EHDE). The study was performed in conformity with the requirements of EU note for guidance “Requirements for the production and Control of immunological veterinary medicinal products (EMA/CVMP/IWP/206555/2010)”, Ph.Eur General Chap. 5.2.7 “Evaluation of efficacy of veterinary vaccines and immunosera” and Ph.Eur Monograph 2448 “Porcine enzootic pneumonia vaccine (inactivated)”. The procedures in this clinical study were performed according to the Code of practice (Good Clinical Practice) for the Conduct of Clinical trials for Veterinary Medical Products and the animals were maintained in accordance with National and European Animal Welfare requirements [–].
: Not applicable.
: Three of the authors (SP, KtH, QC) are employees of the funding body, however, this circumstance did not influence the design of the experimental studies or bias the presentation and interpretation of results. The other authors, declare no conflict of interest.